| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BMS-509744 (BMS509744) is a novel, potent and selective inhibitor of interleukin-2 inducible T cell kinase (ITK) with the potential for immunosuppressive and inflammatory diseases. Its IC50 of 19 nM indicates that it inhibits ITK. It exhibits selectivity over Tec family kinases by 200-fold and selectivity over other tested kinases by 55-fold. BMS-509744 inhibits the spread of HIV infection in vitro and lowers HIV infection of primary CD4+ T cells. In vitro, BMS-509744 also decreases the generation of IL-2 and T cell proliferation.
| Targets |
Itk (IC50 = 19 nM)
|
|---|---|
| ln Vitro |
BMS-509744 inhibits T-cell receptor-induced processes in vitro in both human and mouse cells, such as PLCγ1 tyrosine phosphorylation, calcium mobilization, IL-2 secretion, and T-cell proliferation. BMS-488516 and BMS-509744, with IC50 values of 19 and 96 nM, respectively, potently inhibit Itk in vitro. According to their competitive ATP-binding kinetics, both substances bind to the Itk kinase domain's ATP binding site[1].
|
| ln Vivo |
BMS-509744 and BMS-488516 inhibit the IL-2 production that is brought about by giving mice anti-T-cell receptor antibodies. BMS-509744, regardless of the quantity of induction antibody, demonstrates a 50% inhibitory capacity at 50 mg/kg. In a mouse model of ovalbumin-induced allergy/asthma, BMS-509744 also significantly reduces lung inflammation[1].
|
| Enzyme Assay |
Kinase tests are used to calculate the BMS-509744 activity (IC50). The kinase reactions are carried out with 10 ng of enzyme for 10 min in the presence of 10 μM GST-SLP-76 and different ATP concentrations. The amounts of BMS-509744
|
| Animal Protocol |
Mice: The BMS-509744 and BMS-488516 compounds, or the vehicle (H2O:ethanol:Tween 80) 90:5:5, are injected subcutaneously into Balb/c mice 15 minutes prior to the intravenous injection of anti-CD3 antibody. Ninety minutes after the anti-CD3 antibody is administered, serum is taken for IL-2 and compound levels. Mass spectrometry is used to measure compound levels, and ELISA is used to measure IL-2[1].
|
| References |
| Molecular Formula |
C32H41N5O4S2
|
|---|---|
| Molecular Weight |
623.82904
|
| Exact Mass |
623.26
|
| Elemental Analysis |
C, 61.61; H, 6.62; N, 11.23; O, 10.26; S, 10.28
|
| CAS # |
439575-02-7
|
| Related CAS # |
439575-02-7
|
| Appearance |
Solid powder
|
| SMILES |
CC1=CC(=C(C=C1SC2=CN=C(S2)NC(=O)C3=CC=C(C=C3)CNC(C)C(C)(C)C)C(=O)N4CCN(CC4)C(=O)C)OC
|
| InChi Key |
ZHXNIYGJAOPMSO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H41N5O4S2/c1-20-16-26(41-7)25(30(40)37-14-12-36(13-15-37)22(3)38)17-27(20)42-28-19-34-31(43-28)35-29(39)24-10-8-23(9-11-24)18-33-21(2)32(4,5)6/h8-11,16-17,19,21,33H,12-15,18H2,1-7H3,(H,34,35,39)
|
| Chemical Name |
N-[5-[5-(4-acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl]sulfanyl-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
|
| Synonyms |
CHEMBL209148; BMS509744; BMS-509744; BMS 509744
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~21.9 mg/mL (~35.1 mM）
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6030 mL | 8.0150 mL | 16.0300 mL | |
| 5 mM | 0.3206 mL | 1.6030 mL | 3.2060 mL | |
| 10 mM | 0.1603 mL | 0.8015 mL | 1.6030 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA